ArticleJournal of nanomaterials2012
Nanostructured Surfaces to Target and Kill Circulating Tumor Cells While Repelling Leukocytes.
Article in Journal of nanomaterials, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Targeting circulating tumor cell‒neutrophil interactions: nanoengineered strategies for inhibiting cancer metastasis.Journal of nanobiotechnology · 2025Review
- Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy.Acta pharmaceutica Sinica. B · 2023Article
- Nanomaterials: A Review about Halloysite Nanotubes, Properties, and Application in the Biological Field.International journal of molecular sciences · 2022Review
- Application of Halloysite Nanotubes in Cancer Therapy-A Review.Materials (Basel, Switzerland) · 2021Review
- Peptide functionalized liposomes for receptor targeted cancer therapy.APL bioengineering · 2021Review
- Is small smarter? Nanomaterial-based detection and elimination of circulating tumor cells: current knowledge and perspectives.International journal of nanomedicine · 2019Review
- Circulating Tumour Cell Release after Cement Augmentation of Vertebral Metastases.Scientific reports · 2017Article
- Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells.Chemical Society reviews · 2017Review
- Nanomaterials for the Capture and Therapeutic Targeting of Circulating Tumor Cells.Cellular and molecular bioengineering · 2017Review
- Lamin A/C deficiency reduces circulating tumor cell resistance to fluid shear stress.American journal of physiology. Cell physiology · 2015Article
- Immobilized surfactant-nanotube complexes support selectin-mediated capture of viable circulating tumor cells in the absence of capture antibodies.Journal of biomedical materials research. Part A · 2015Article
- Surfactant functionalization induces robust, differential adhesion of tumor cells and blood cells to charged nanotube-coated biomaterials under flow.Biomaterials · 2015Article
- Leukocytes as carriers for targeted cancer drug delivery.Expert opinion on drug delivery · 2015Review
- Small molecule PZL318: forming fluorescent nanoparticles capable of tracing their interactions with cancer cells and activated platelets, slowing tumor growth and inhibiting thrombosis.International journal of nanomedicine · 2015Article
- Synthesization, Characterization, andMaterials (Basel, Switzerland) · 2014Article
- Effects of nanopillar array diameter and spacing on cancer cell capture and cell behaviors.Nanoscale · 2014Article
- Unnatural killer cells to prevent bloodborne metastasis: inspiration from biology and engineering.Expert review of anticancer therapy · 2014Article
- Fluid shear stress increases neutrophil activation via platelet-activating factor.Biophysical journal · 2014Article
- Physical biology in cancer. 3. The role of cell glycocalyx in vascular transport of circulating tumor cells.American journal of physiology. Cell physiology · 2014Review
- Stem cell enrichment with selectin receptors: mimicking the pH environment of trauma.Sensors (Basel, Switzerland) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Hematogenous metastasis, the process of cancer cell migration from a primary to distal location via the bloodstream, typically leads to a poor patient prognosis. Selectin proteins hold promise in delivering drug-containing nanocarriers to circulating tumor cells (CTCs) in the bloodstream, due to their rapid, force-dependent binding kinetics. However, it is challenging to deliver such nanocarriers while avoiding toxic effects on healthy blood cells, as many possess ligands that adhesively interact with selectins. Herein, we describe a nanostructured surface to capture flowing cancer cells, while preventing human neutrophil adhesion. Microtube surfaces with immobilized halloysite nanotubes (HNTs) and E-selectin functionalized liposomal doxorubicin (ESPEG L-DXR) significantly increased the number of breast adenocarcinoma MCF7 cells captured from flow, yet also significantly reduced the number of captured neutrophils. Neutrophils firmly adhered and projected pseudopods on surfaces coated only with liposomes, while neutrophils adherent to HNT-liposome surfaces maintained a round morphology. Perfusion of both MCF7 cells and neutrophils resulted in primarily cancer cell adhesion to the HNT-liposome surface, and induced significant cancer cell death. This work demonstrates that nanostructured surfaces consisting of HNTs and ES-PEG L-DXR can increase CTC recruitment for chemotherapeutic delivery, while also preventing healthy cell adhesion and uptake of therapeutic intended for CTCs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.